Pharmaceuticals Europe

Europe Psychedelic Therapeutics Market Analysis, 2024–2034

Europe Psychedelic Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Compound, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Europe · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $637.0 Mn Estimated value
Estimate 2025 $709.6 Mn 18.5% of the global market
Projected 2034 $1.87 Bn 164.2% Adds $1.17 Bn over 9 forecast years
CAGR 2025–2034 11.4% Faster than 70% of 180 Pharmaceuticals markets here
Key players 5 Companies profiled
  • Europe is 18.52% of the global market.
  • Among regions, the largest is North America at $2.06 Bn.
  • Fastest growing: APAC at 14.4% a year.
  • Europe ranks 3rd of 6 by size among regions.

Market size projection

Europe

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.17 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Psychedelic Therapeutics Market market size by year, Europe
YearMarket sizeChange that yearSince 2025
2024 (estimate) $637.0 Mn — —
2025 (base) $709.6 Mn +$72.6 Mn —
2026 (forecast) $790.5 Mn +$80.9 Mn +11.4%
2027 (forecast) $880.6 Mn +$90.1 Mn +24.1%
2028 (forecast) $981.0 Mn +$100.4 Mn +38.2%
2029 (forecast) $1.09 Bn +$111.8 Mn +54%
2030 (forecast) $1.22 Bn +$124.6 Mn +71.6%
2031 (forecast) $1.36 Bn +$138.8 Mn +91.1%
2032 (forecast) $1.51 Bn +$154.6 Mn +112.9%
2033 (forecast) $1.68 Bn +$172.2 Mn +137.2%
2034 (forecast) $1.87 Bn +$191.9 Mn +164.2%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $3.83 Bn
  2. North America $2.06 Bn
  3. US $1.55 Bn
  4. APAC $765.0 Mn
  5. Europe (this report) $709.6 Mn
  6. China $325.4 Mn
  7. Canada $276.7 Mn
  8. Japan $237.6 Mn
  9. Latin America $163.3 Mn
  10. Middle East $151.4 Mn
  11. Germany $120.6 Mn
  12. UK $109.5 Mn
  13. France $108.8 Mn
  14. Italy $101.7 Mn
  15. Brazil $88.9 Mn
  16. Ecuador $78.0 Mn
  17. India $80.7 Mn
  18. Saudi Arabia $71.7 Mn
  19. Spain $67.7 Mn
  20. Mexico $65.2 Mn
  21. Africa $66.4 Mn
  22. Australia $45.3 Mn
  23. New Zealand $42.8 Mn
  24. Russia $33.5 Mn
  25. South Africa $24.5 Mn
  26. UAE $18.5 Mn
  27. Egypt $9.8 Mn
  28. Philippines $8.0 Mn
  29. Hong Kong $6.3 Mn
  30. Malaysia $5.4 Mn
  31. Thailand $5.3 Mn
  32. Singapore $5.0 Mn
  33. Kenya $2.5 Mn

The Europe Psychedelic Therapeutics Market Analysis Executive Summary

Psychedelic therapeutics use compounds such as psilocybin, MDMA and LSD with therapy support to treat depression, PTSD and addiction.

Key segments of the psychedelic Therapeutics market include compound (Psilocybin, MDMA and LSD) and indication (Treatment-Resistant Depression, PTSD and Substance Use Disorder).

Europe Psychedelic Therapeutics Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the psychedelic Therapeutics market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the psychedelic Therapeutics market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the psychedelic Therapeutics market.

Competitive Landscape for Psychedelic Therapeutics Market in Europe

The psychedelic Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Psychedelic Therapeutics Market in Europe

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for psychedelic Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Psychedelic Therapeutics right now, from free public sources.

Clinical trials

9 active trials in UK, Germany, France, Italy, Spain and Russia

Recruiting, about to start, or running now. Counted across the 6 countries we report on in Europe.

Top trial sponsors (worldwide)

  1. Compass Pathways 3 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 30 papers since 2021 (worldwide)

  1. Evolutionary neuropharmacology of serotonergic psychedelics: a cross-species perspective on mechanisms, consciousness, and therapeutic potential. Molecular psychiatry, 2026
  2. Advancing Next-Generation Psychedelic Therapeutics through Selective 5‑HT2A Activation, Precision Aerosol Delivery, and Optimized 5‑MeO-DMT Treatment Paradigms. ACS medicinal chemistry letters, 2026
  3. The Timing of Plasticity: Beyond Synapses in Psychedelic Therapeutics. Biological psychiatry, 2026
  4. Molecules, meaning, and physiology: disentangling the active ingredients of psychedelic therapeutics. Frontiers in neuroscience, 2026
  5. Thalamic 5-HT(2A) receptor activation reduces GABA uptake, increases tonic GABA(A) inhibition and induces absence seizures in Wistar rats. Neuropharmacology, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Psychedelic Therapeutics in context

Questions, answered with public data

How many clinical trials on Psychedelic Therapeutics are running in Europe?
9 studies are recruiting, active or about to start in Europe, counted across the 6 countries we report on there.[1]
How much research is published on Psychedelic Therapeutics?
PubMed lists 30 papers added since January 2021 that match this market, worldwide.[2]

[1] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.

[2] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Psychedelic Therapeutics in Europe? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Adaptogens: Ancient Herbs, Modern Market170 WHO Member States report the use of traditional medicine. Adaptogens like ashwagandha, rhodiola and… Stress and Mood Supplements: Ashwagandha and BeyondDepression and anxiety cost the world about US$1 trillion a year. Ashwagandha has some evidence for stress… Antidepressants: Demand, Access and New ApproachesAbout 322 million people live with depression. Treatment works, but most people still do not get it.
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Europe

See all
Same topic, other categories

Related on mental health

See the topic